Zenicor (ZENI) Q3 2025 earnings summary

Executive summary

• Revenue for Q3 2025 reached 5,777 KSEK, a 10% increase year-over-year, marking the best third quarter to date.

• Operating profit for Q3 2025 was positive at 100 KSEK, consistent with the prior year.

• Growth driven by high usage among existing customers and successful onboarding of new clients.

• Strategic focus on partnerships, notably with Medicalgorithmics, to enhance AI-driven arrhythmia diagnostics.

Financial highlights

• Revenue for Q3 2025: 5,777 KSEK (Q3 2024: 5,268 KSEK), up 10% year-over-year.

• Operating profit for Q3 2025: 100 KSEK (Q3 2024: 110 KSEK).

• Operating profit per share: 0.01 SEK (unchanged year-over-year).

• Net result for the first nine months: -997 KSEK (2024: -2,602 KSEK).

Outlook and guidance

• Capital raised through a rights issue is intended to support growth to sustainable profitability and positive cash flow in 2026.

• Continued focus on expanding partnerships and integrating advanced AI solutions.